Sanuwave Health withdrew its full-year 2026 revenue guidance due to uncertainty surrounding proposed CMS reimbursement changes. Second-quarter revenue fell 3% year over year to $9.7 million, as a 34% decline in UltraMIST system sales offset continued growth in recurring applicator revenue. Applicator units rose 27% year over year, while active systems increased to 1,411 from 1,382 in the first quarter. Profitability weakened as gross margin fell to 76.2%, the company posted a $0.7 million net loss versus prior-year income of $0.6 million, and adjusted EBITDA declined to $1.2 million from $3.2 million. The company estimates physician-office reimbursement could decline from about $397 currently to $316 in 2027 if the proposal is finalized, while hospital outpatient reimbursement could rise 14%.
SANUWAVE Health, Inc. Common StockCMS reimbursement uncertainty and potential physician-office rate cut from $397 to $316 in 2027, plus withdrawn 2026 guidance.
